Real-time observation in stem cells helpful in vascular disease: Study – Health

A recent study found that stem cell treatment for vascular disease can be predicted through real-time observation.

In the study, published in the journal Biomaterials, the prediction of therapeutic efficacy was performed using initial distribution images of stem cells that are different from endothelial cells. It can be applied to research on stem cell treatment for blood vessel regeneration.

In recent years, due to an increase in the number of people with obesity, diabetes, and high blood pressure triggered by changes in eating habits, smoking, the number of high-risk groups for ischemic diseases such as critical limb ischemia, in which the tissues of the toe may break down, has increased due to an increase in the number of people with obesity, diabetes, and high blood pressure triggered by changes in eating habits, smoking and alcohol consumption. A number of studies are actively being carried out on endothelial progenitor cells (hEPCs), which are stem cells that help regenerate blood vessels in ischemic tissues to treat such ischemic diseases.

Vascular hEPCs migrate to regions that require angiogenesis, such as B. ischemic regions, and then differentiate into endothelial cells of blood vessels or release growth factors that aid in the formation of blood vessels to induce regeneration of the damaged blood vessels. Therefore, these cells can be developed for stem cell therapy for blood vessel-related diseases, including ischemic diseases.

However, when the hEPCs with excellent blood vessel regeneration ability are used as stem cell therapy in ischemic diseases, the effectiveness of the therapeutic treatment may differ depending on various variables such as the survival of the transplanted cells and the migration to the treatment region. Accordingly, treatments for ischemic diseases remain in the clinical stage without being commercialized because of the limitations in closely monitoring and predicting therapeutic efficacy.

The Korea Institute of Science and Technology (KIST) recently announced that the Dr. Kwangmeyung Kim from the Center for Theragnosis and Sung-Hwan Moon from the Stem Cell Research Institute, T&R Biofab Co. Ltd., developed a method to predict the therapeutic efficacy based on the distribution of the initial transplant of hEPCs by following the initial distribution and migration of the transplanted cells using fluorescent chromographic images.

The KIST research team initially made it possible to observe fluorescence signals using fluorescence molecular tomography by binding fluorescent dyes to the surface of hEPCs. The team then transplanted the cells with severe ischemia into the mouse’s hindquarters and imaged them for 28 days to assess cell movement in the body. The regeneration process of the blood flow was then followed and observed using a laser scanning microscope (laser Doppler imaging). As a result, it was shown that the hEPCs migrate to the damaged tissues where ischemic disease is found.

In addition, it was observed that the shapes of cell clusters were injected into two different shapes as a result of the analysis of the images of hEPCs during the initial transplantation of the cell therapy treatment. The two shapes were condensed round shape and dispersed shape. When the therapeutic efficacy was observed by classifying the experimental groups into these two forms, it was found that the “round shape” initially condensed cells migrated better and exhibited superior therapeutic efficacy in the experimental groups. Based on these findings, the research team predicted that if the treatment cells were formed into a condensed “round shape” during the initial treatment, the effectiveness of the treatment will be superior.

“The technology we have developed to quickly and accurately monitor initial transplant forms and changes in stem cell therapy will make it possible to predict the effectiveness of transplanted hEPCs in the early stages of ischemic disease treatment and we expect them to be used in development will be of stem cell therapies for ischemic diseases in the future, ”said Dr. Kwangmeyung Kim from KIST who led the research.

(This story was posted from a wire agency feed with no text changes. Only the headline was changed.)

Follow more stories on Facebook and Twitter